Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03779906 · ClinicalTrials.gov registry record · Phase 4
Thyroid Function of Pediatric Subjects Following Isovue® Administration
A Phase 4 study, sponsored by Bracco Diagnostics.
- Terminated
- Registry status
- Phase 4
- Development phase
- 17
- Enrollment target
NCT03779906 is a Phase 4 study that was terminated before completion, run by Bracco Diagnostics. The registered enrollment target is 17 participants.
The verdict
NCT03779906, a Phase 4 study, was terminated before completion, sponsored by Bracco Diagnostics.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 17 participants
- Enrollment target
Study Summary
This is a Phase IV prospective, multicenter, observational study to estimate the proportion of subjects 0 to 3 years of age who develop abnormal thyroid function after exposure to intravascular administration of ISOVUE for the required radiologic procedure as part of their standard of care.
Interventions
- DRUG Isovue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-03-26 |
| Est. Completion | 2022-03-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03779906
The ClinicalTrials.gov registry entry for NCT03779906 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bracco Diagnostics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Isovue is the first listed.
NCT03779906 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03779906 about?
NCT03779906 is a clinical study titled "Thyroid Function of Pediatric Subjects Following Isovue® Administration". This is a Phase IV prospective, multicenter, observational study to estimate the proportion of subjects 0 to 3 years of age who develop abnormal thyroid function after exposure to intravascular administration of ISOVUE for the required radiologic procedure as part of their standard of care.
What is the current status of trial NCT03779906?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 17 participants. The study started on 2019-03-26. Estimated completion is 2022-03-25.
What interventions are being tested in trial NCT03779906?
The interventions under investigation include: Isovue (DRUG).
Who is sponsoring clinical trial NCT03779906?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.